Longevity Peptide Stack — NAD+ + MOTS-c + Tesamorelin Research and Mechanisms

Longevity research has matured past single-compound interventions. The 2013 López-Otín "hallmarks of aging" framework identified twelve interrelated mechanisms — mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, and altered intercellular communication among them. A longevity peptide stack that targets multiple hallmarks at once has a better mechanistic case than betting on any single compound. The NAD+ + MOTS-c + Tesamorelin combination is the most-discussed research stack in Dubai's longevity-clinic-adjacent peptide community.

1. The hallmarks-of-aging framework

López-Otín et al. 2013 (and the 2023 update extending to twelve hallmarks) provides the mechanistic map that longevity-research peptide selection follows. Of the twelve hallmarks, peptide-tractable ones include:

• Mitochondrial dysfunction — declining respiratory chain efficiency, ROS accumulation
• Deregulated nutrient sensing — IGF-1, mTOR, AMPK, sirtuin axis
• Loss of proteostasis — declining protein quality control
• Altered intercellular communication — including hormonal signalling
• Stem cell exhaustion — declining regenerative capacity

The three-peptide stack targets the first two hallmarks directly (mitochondrial dysfunction, deregulated nutrient sensing) and modulates the fourth (intercellular communication via GH/IGF-1 axis).

2. The three peptides — what each one does

3. NAD+ — the coenzyme substrate

NAD+ declines roughly 50% between ages 30 and 60 (Camacho-Pereira 2016, Massudi 2012). The decline correlates with — but doesn't necessarily cause — multiple aging hallmarks. The functional consequence is reduced sirtuin and PARP activity, both of which require NAD+ as substrate. Restoring NAD+ to younger-adult levels is the proposed lever.

Clinic settings and research protocols use different administration routes and formats; REVIVE LAB UAE does not provide guidance on route or amount for any compound. Full NAD+ context sits in our NAD+ vs NMN vs NR comparison.

4. MOTS-c — the mitochondrial signal

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome — discovered by Lee, Cohen et al. in 2015. The peptide translocates out of the mitochondrion under metabolic stress and acts as an exercise-mimetic signal: AMPK activation, increased glucose uptake, increased fatty acid oxidation. Reynolds et al. 2021 showed MOTS-c administration in aged mice extended running endurance by ~70%.

The full mechanism walkthrough sits in our MOTS-c protocol research writeup.

5. Tesamorelin — the GH/IGF-1 axis

GH secretion declines roughly 14% per decade from age 20 onward (Veldhuis 2005). The decline contributes to sarcopenia, visceral fat accumulation, and reduced regenerative capacity. Falutz 2010 + Stanley 2014 show measurable visceral fat reduction + lean mass preservation/gain.

In the longevity stack, Tesamorelin addresses the GH/IGF-1 hallmark while contributing to body-composition endpoints that overlap with healthspan markers.

6. Mechanistic complementarity

The three peptides hit complementary points in mitochondrial and metabolic biology:

• NAD+ provides substrate for the enzymes that sense nutrient state and DNA damage
• MOTS-c sends the upstream stress signal that activates the broader metabolic-response network
• Tesamorelin drives the systemic anabolic/catabolic balance via GH/IGF-1

None of the three directly substitutes for any of the others. The mechanistic case for the stack is strong; the lack of combined-trial data is the limitation.

7. Research design considerations

Published research on each of these three compounds individually spans study durations from several weeks to several months (see references below for the specific trials). None of the three has a published trial studying the combination together, so there is no established combined-study timeline to cite. REVIVE LAB UAE does not publish or provide dosing, cycling, administration route, or scheduling guidance for this or any compound — that determination sits entirely within the researcher's own institutional protocol and ethical review framework, not with a research-chemical supplier.

8. Handling and reconstitution

Each of the three compounds ships as its own separate lyophilized vial and is reconstituted individually per its own spec — never combined into one solution. MOTS-c and Tesamorelin use bacteriostatic water; NAD+ (when in stock) is compatible with sterile or bacteriostatic water. REVIVE LAB UAE does not provide guidance on administration route, injection site, or scheduling for any compound. The full vial-concentration math (mixing ratios, not administration guidance) sits in our peptide reconstitution calculator.

9. Tracking — what longevity research actually measures

Lifespan endpoints are decade-scale and unmeasurable within any single research study. The proxy endpoints longevity research uses instead:

• Body composition: DEXA scan at baseline and at follow-up (lean mass, visceral fat, total fat)
• Metabolic markers: Fasting glucose, HbA1c, fasting insulin, lipid panel
• IGF-1: Baseline plus follow-up testing per the researcher's own protocol (Tesamorelin-driven elevation should sit within physiologic range)
• VO2 max or equivalent endurance metric: Useful for MOTS-c exercise-mimetic endpoint
• Sleep quality: Tesamorelin can improve deep-sleep proportion (GH-pulse-dependent)
• Subjective energy / cognition: Validated questionnaires (PROMIS, etc.) if available

10. The Dubai longevity-clinic context

Dubai's licensed longevity-clinic sector typically prices supervised NAD+ and Tesamorelin programs at AED 4,000-8,000 per month, administered under clinical supervision. Research-grade peptides purchased for laboratory use are priced on a per-vial basis and are not a substitute for clinical treatment — REVIVE LAB UAE sells research-use compounds only and does not provide, recommend, or facilitate any self-administration protocol.

Anyone considering human use of any compound should consult a licensed physician; this page and REVIVE LAB UAE's products are not intended for that purpose.

12. The caveats

• No combined-stack trial. This page synthesises separately-published mechanism evidence for each compound individually; no published trial has tested the three together.
• Lifespan claims are unsupported. Healthspan markers are the measurable endpoint in published research, not "anti-aging" in a literal sense.
• Tesamorelin and IGF-1 elevation. Published literature notes cancer-screening and family-history considerations are relevant to GHRH-axis research generally — a matter for a researcher's own institutional and medical oversight, not something this page advises on.
• Documented side effects. Published clinical literature on NAD+ and Tesamorelin documents injection-site reactions among other effects — see the individual compound research pages for details. This page does not provide administration guidance.
• Cost. Three separate research-grade compounds are a larger laboratory expenditure than a single-compound purchase.

13. The summary

• NAD+, MOTS-c, and Tesamorelin target three different points in mitochondrial and metabolic biology, each with its own separately published research base.
• No published trial has studied the three-compound combination together.
• Each ships and is reconstituted as its own separate vial — never combined into one solution. REVIVE LAB UAE does not provide dosing, cycling, or administration guidance for any compound.
• Dubai's licensed longevity-clinic sector prices supervised programs at AED 4,000-8,000/month; research-grade compounds are priced per-vial for laboratory use and are not a clinical substitute.
• MOTS-c and Tesamorelin are HPLC-verified and in stock at REVIVE LAB UAE with lot-level COA (NAD+ temporarily out of stock).